{"id":257,"date":"2019-05-09T15:11:00","date_gmt":"2019-05-09T15:11:00","guid":{"rendered":"https:\/\/www.oncostem.com\/blog\/?p=257"},"modified":"2025-07-22T15:23:26","modified_gmt":"2025-07-22T15:23:26","slug":"chemotherapy-or-no-chemotherapy-canassist-breast-helps-you-decide","status":"publish","type":"post","link":"https:\/\/www.oncostem.com\/blog\/chemotherapy-or-no-chemotherapy-canassist-breast-helps-you-decide\/","title":{"rendered":"Chemotherapy Or No Chemotherapy \u2013 CanAssist Breast Helps You Decide"},"content":{"rendered":"\n

What comes to your mind when you think about breast cancer? It would most probably be \u2018chemotherapy,\u2019 \u2018fear of a long process of treatment,\u2019 \u2018high costs,\u2019 the fear of cancer coming back, and so on. These thoughts can be controlled with the right knowledge and right breast cancer treatments.<\/p>\n\n\n\n

Researchers and oncologists have made new and promising forms of treatment for breast cancer. It\u2019s time to personalize your treatment!<\/h4>\n\n\n\n

Our test classi\ufb01es patients as \u2018low-risk\u2019 or \u2018high-risk\u2019 based on the patient\u2019s breast cancer recurrence risks over five years. The clear-cut test result provides doctors with additional information that can be used for treatment planning.<\/p>\n\n\n\n

\"Plan-the-ideal-treatment-blog-Breast
Plan-the-ideal-treatment-blog-Breast Cancer Risk, Breast cancer test, breast cancer treatment, CanAssist Breast Prognostic Test, Prognostic Test on Breast Cancer\n<\/figcaption><\/figure>\n\n\n\n

Plan the ideal treatment<\/h4>\n\n\n\n

CanAssist Breast is a test that helps to plan the ideal treatment by predicting the breast cancer recurrence risk within five years of surgery. The risk of recurrence is lesser in early-stage breast cancer (Stage 1 and Stage 2), and hence, it is important for doctors and the patients to plan out a suitable course of treatment based on the breast cancer recurrence risk score.<\/p>\n\n\n\n

Until a few years back, oncologists and clinicians were deciding cancer treatments based on age, tumor size, node status, grade, ER, PR and HER2 status. OncoStem, with the invention of CanAssist Breast aims to fill the gap in understanding the tumor biology to comprehend the progression and its aggressiveness. CanAssist Breast helps personalise treatment depending on an individual\u2019s tumor biology. With the benefit of validation on Indian breast cancer patients, CanAssist Breast helps in predicting the risk of recurrence accurately.<\/p>\n\n\n\n

Tests similar to CanAssist Breast have been based on genomic analysis, whereas CanAssist Breast involves proteomics analysis. The genomics method considers genes of interest in the genome of a cell, whereas CanAssist Breast\u2019s proteomics technique studies the proteins of interest produced by the cell. A 5-year study<\/a> by OncoStem Diagnostics, recently published online, explains the detailed analysis and results that lead to the test, CanAssist Breast.<\/p>\n\n\n\n

Your tumor is different, just like you are, as an individual.<\/p>\n\n\n\n

Doctors and oncologists have to know as much possible about your tumor for optimal and ideal treatment.<\/h6>\n\n\n\n
\"Plan-the-ideal-treatment-blog-Breast

A way forward \u2013 scientific, machine-learning precision<\/strong>

Artificial intelligence and machine learning is an emerging approach in the healthcare sector including the treatment of breast cancer. CanAssist Breast is the first such test developed in India, specifically for Indian patients. It determines the tumor\u2019s biochemical fingerprint and assesses its aggressiveness. Assessing the tumor biology in detail, the test considers five key biomarkers that are involved in recurrence-related pathways in the cell. Based on this combined analysis performed by proteomics-based technology, the information is then assessed by a statistical algorithm that provides a score between 0 and 100 \u2013 whether the patient is at low-risk or high-risk for cancer recurrence. A \u2018CAB risk score\u2019 less than 15.5 indicates a low-risk. Depending on each patient\u2019s unique CAB risk score, the doctors can thus plan an ideal treatment tailored to an individual\u2019s patient.

A decision that doctors and patients must make:
<\/strong>
\u2018Fear\u2019\u00a0is the most shared and challenging emotion that cancer brings with it. However, fearful a patient might be; it is essential for the patients to know and consider that their treatment can be different from that of the other patients.

Knowing who is eligible for the CanAssist-Breast test can help both patients and doctors.<\/strong>

The patients must meet the below criteria to take CanAssist Breast:<\/figcaption><\/figure>\n\n\n\n